Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
US8337856B2 · kind B2 · utility
65Cited by
81References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 3, 2007 |
| Grant date | Dec 25, 2012 |
| Priority date | — |
| Expiry date | Mar 21, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.